Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025British Journal of Haematology

A decade of experience using ATG and PTCy for graft‐versus‐host disease prophylaxis in matched unrelated donor allogeneic haematopoietic cell transplantation

View Full Paper
Ask AI
Bookmark
Share

Authors

NDNihar DesaiSRSergio Rodríguez‐RodríguezEAEshrak Al‐Shaibani

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows low-dose ATG and PTCy reduces GvHD in patients, indicating a promising prophylaxis strategy.

Key Points

  • Grade III-IV acute graft-versus-host disease was observed in only 7% of patients at day 100 post-transplant.
  • Significant cytomegalovirus and Epstein-Barr virus reactivation occurred in 20.4% and 22.7% of patients by D+180.
  • Overall survival at 24 months was 68.3%, showcasing the efficacy of the combined preventive strategy.
  • Graft-versus-host disease-free survival at 24 months was 49%, supporting further exploration of this therapy.

Cite This Study

Desai et al. (2025) studied this question.

synapsesocial.com/papers/68c23887b210217d64777a8ehttps://doi.org/10.1111/bjh.70124
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Exploring the efficacy and safety of low-dose ATG combined with fractionated low-dose ptcy in preventing gvhd after allogeneic hematopoietic stem cell transplantation2025 · 1 citations
  2. 2Post-transplant cyclophosphamide (PTCy) versus other graft-versus-host disease prophylaxis strategies in reduced intensity allogeneic stem cell transplantation from related and matched unrelated donors in patients with acute myeloid leukemia and myelodysplastic syndromes: A study from the french society of bone marrow transplantation (SFGM-TC) registry2025
  3. 3Impact of the addition of antithymocyte globulin to post-transplantation cyclophosphamide in haploidentical transplantation with peripheral blood compared to post-transplantation cyclophosphamide alone: A retrospective study on behalf of the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation.2025 · 5 citations
  4. 4Reduced dose post-transplant cytoxan (Intermediate -Dose) in combination with abatacept after matched unrelated donor transplant for high -risk hematological malignancy may reduce treatment related mortality and risk of relapse.2025
  5. 5Post-transplant cyclophosphamide improves survival compared to antithymocyte globulin in HLA-mismatched unrelated donor stem cell transplantation2025 · 1 citations